DTIL
Precision BioSciences, Inc.
There isn't enough reported data to score DTIL yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
DTIL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Unavailable |
DTIL's revenue is currently healthy, and its profitability is stable, but its cash flow is under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
DTIL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 22x | $7.23 | -10% |
| Current | 24x | $8.04 | — |
| Fair | 31x | $10.17 | +26% |
| Expensive | 35x | $11.52 | +43% |
Historical ranges are pointers, not guarantees.
DTIL's PE is 24x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over DTIL in the historical PE scenario, which offers more potential upside but is not a forecast.
DTIL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect DTIL's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
DTIL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.33 | +$9.59 |
| Q2 2026 | -$1.23 | +$8.44 |
| Q1 2026 | -$2.10 | +$0.77 |
| Q4 2025 | -$3.56 | -442% |
| Q3 2025 | -$9.26 | -5888% |
| Q2 2025 | -$9.67 | -3219% |
| Q1 2025 | -$2.87 | +$4.49 |
| Q4 2024 | $1.04 | +$17.00 |
DTIL has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
DTIL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $10.8M | +37272% |
| Q4 2025 | $34.2M | +5261% |
| Q3 2025 | $13K | -98% |
| Q2 2025 | $18K | -100% |
| Q1 2025 | $29K | -100% |
| Q4 2024 | $638K | -91% |
| Q3 2024 | $576K | -96% |
| Q2 2024 | $49.9M | +152% |
DTIL's revenue is growing: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -84% | +76165 points |
| Q4 2025 | 37% | +3931 points |
| Q3 2025 | -158977% | -155283 points |
| Q2 2025 | -121539% | -121587 points |
| Q1 2025 | -76248% | -76225 points |
| Q4 2024 | -3894% | -3683 points |
| Q3 2024 | -3694% | -3599 points |
| Q2 2024 | 48% | +109 points |
DTIL's operating margin was −84% last quarter, up 76165 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over DTIL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
DTIL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.1M | +$138K |
| Q2 2026 | -$13.4M | +$6.8M |
| Q1 2026 | -$12M | +$7.2M |
| Q4 2025 | -$11.3M | +$7.5M |
| Q3 2025 | -$15.3M | -$9.3M |
| Q2 2025 | -$20.3M | -$5.4M |
| Q1 2025 | -$19.1M | -$49K |
| Q4 2024 | -$18.8M | -$10.4M |
DTIL has burned cash in almost every quarter: −$52M over the past year, against −$73M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over DTIL on cash generation, producing positive trailing cash flow while its opponent burns cash.
DTIL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +6.1% | +1.6M shares |
| 1 year | +148% | +16.4M shares |
| 3 years | +642% | +23.7M shares |
| 5 years | +1472% | +25.7M shares |
DTIL has 27M diluted shares, up 148% from a year ago.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over DTIL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
DTIL Net Leverage
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
DTIL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.8 | Neutral |
| Stochastic | 55.4 | Neutral |
DTIL's weekly RSI is 54 (neutral) and its Stochastic is 55 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
DTIL PE vs Healthcare Sector
| Metric | DTIL | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 26x | 5.8% below |
| PE % | 17 | 29 | 12 pts below |
DTIL is trading at 24x earnings, in line with the Healthcare sector's median of 26x, though its earnings don't support one.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over DTIL on valuation relative to its sector.
DTIL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.17 | 12% above |
| 20 week MA | $7.47 | 7.6% above |
| 50 week MA | $6.35 | 27% above |
| 100 week MA | $5.75 | 40% above |
| 200 week MA | $10.3 | 22% below |
DTIL has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 22% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over DTIL on trend strength, trading above more of its moving averages.
DTIL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $421.5 | $280.5 | -33% |
| 2021 | $280.5 | $254.1 | -9.4% |
| 2022 | $254.1 | $30.3 | -88% |
| 2023 | $30.3 | $11.0 | -64% |
| 2024 | $11.0 | $4.65 | -58% |
| 2025 | $4.65 | $4.23 | -9% |
| 2026 YTD | $4.23 | $8.04 | +90% |
DTIL has finished every year since 2020 lower, and it's up 90% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over DTIL on returns for 2026, with the stronger performance.